Finding a safe weight loss pill is a priority for many people in the UK seeking medical support for obesity or overweight. With a growing number of products available — from NHS-prescribed medicines to unregulated supplements sold online — understanding which treatments are genuinely safe, clinically approved, and appropriate for your circumstances is essential. This article explains how weight loss medicines are assessed for safety by the MHRA, which treatments are currently approved for use in the UK, who may be eligible, what side effects to expect, and how to access treatment safely through the NHS or a regulated provider.

How Weight Loss Medicines Are Assessed for Safety in the UK

Before any weight loss medicine can be prescribed or sold in the UK, it must undergo a rigorous regulatory approval process. The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK authority responsible for evaluating the safety, quality, and efficacy of all medicines used in Great Britain. For a weight loss treatment to receive approval, manufacturers must submit extensive clinical trial data demonstrating that the benefits of the medicine outweigh its potential risks in the intended patient population.

Following the UK's departure from the EU, the European Medicines Agency (EMA) no longer authorises medicines for use in Great Britain. EMA marketing authorisations continue to apply in Northern Ireland under the Windsor Framework, and the MHRA has established recognition routes for certain international approvals, but UK marketing authorisation decisions are made by the MHRA. NICE (the National Institute for Health and Care Excellence) then evaluates whether MHRA-approved medicines are clinically effective and cost-effective for use within the NHS, issuing guidance that informs prescribing decisions across England and Wales.

It is important to understand that the term 'safe' in a medical context does not mean 'without any risk'. Rather, it means that a medicine's benefits have been judged to outweigh its risks when used appropriately, in the right patients, under medical supervision. Weight loss medicines that are not MHRA-approved — including many products sold online or through unregulated channels — have not been subject to this scrutiny and may pose serious health risks. Patients are strongly advised to seek weight loss treatments only through regulated healthcare providers.

Once a medicine is in use, its safety continues to be monitored through pharmacovigilance. Patients and healthcare professionals are encouraged to report any suspected side effects via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk), which helps identify new or changing safety signals.

NHS-Approved Weight Loss Treatments Currently Available

Currently, there are a small number of weight loss medicines that are approved for use in the UK and may be prescribed within the NHS under specific clinical criteria. The most established of these is orlistat (brand name Xenical), which has been available for many years and is also available over the counter in a lower-dose form (Alli, 60 mg). Orlistat works by inhibiting pancreatic and gastric lipases — enzymes responsible for breaking down dietary fat in the gut. By blocking approximately one-third of dietary fat absorption, it helps reduce overall calorie intake.

More recently, semaglutide (Wegovy) has been approved by the MHRA and received a positive NICE technology appraisal (TA875) for use in adults with obesity or overweight with at least one weight-related comorbidity. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, originally developed for type 2 diabetes management. It works by mimicking the GLP-1 hormone, which regulates appetite and food intake by acting on receptors in the brain, slowing gastric emptying, and promoting a feeling of fullness. It is administered as a once-weekly subcutaneous injection rather than an oral pill.

Liraglutide (Saxenda), another GLP-1 receptor agonist given as a daily subcutaneous injection, is also approved for weight management in the UK under NICE TA664. NICE guidance specifies that these newer agents should be used as part of a specialist weight management service, alongside dietary and lifestyle interventions, rather than as standalone treatments. For liraglutide specifically, treatment should be discontinued if a patient has not lost at least 5% of their initial body weight after 12 weeks at the full maintenance dose of 3 mg daily.

It is worth noting that some medicines may hold an MHRA licence but have not yet received a positive NICE recommendation for routine NHS commissioning. NHS availability is determined by NICE guidance rather than licensing status alone.

Who May Be Suitable for a Prescribed Weight Loss Pill

Weight loss medicines are not appropriate for everyone, and eligibility is determined by clinical criteria rather than personal preference. According to NICE guidance (CG189), orlistat may be considered for adults who:

• Have a BMI of 30 kg/m² or above, or

• Have a BMI of 28 kg/m² or above with associated risk factors such as type 2 diabetes, hypertension, or raised cholesterol

• Have already made a genuine attempt to lose weight through diet and exercise alone

For people from South Asian, Chinese, and Black ethnic backgrounds, NICE recommends using lower BMI thresholds (reduced by approximately 2.5 kg/m²), as the health risks associated with excess weight occur at lower BMI values in these groups.

Orlistat should only be continued beyond three months if the patient has lost at least 5% of their initial body weight from the start of treatment (or at least 3% if the patient has type 2 diabetes). If these targets are not met, the medicine is unlikely to be beneficial and should be stopped.

For semaglutide (Wegovy), NICE TA875 recommends it for adults with a BMI of 35 kg/m² or above alongside at least one weight-related health condition, or for those with a BMI between 30 and 34.9 kg/m² who meet specific criteria. Ethnicity-adjusted thresholds also apply. It is currently recommended for use within specialist NHS weight management services for a maximum of two years.

For liraglutide (Saxenda), similar BMI criteria and specialist service requirements apply under NICE TA664, with the stopping rule described above.

Certain groups are not suitable for weight loss medicines. These include pregnant or breastfeeding women, individuals with chronic malabsorption syndrome (for orlistat), and those with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2) — both of which are contraindications for GLP-1 receptor agonists. A thorough medical assessment — including a review of current medications, medical history, and cardiovascular risk — is essential before any weight loss medicine is initiated. Patients should always be honest with their prescriber about their full medical history to ensure the safest and most appropriate treatment is selected.

Potential Side Effects and Risks to Be Aware Of

As with all medicines, weight loss treatments carry the potential for side effects, and patients should be fully informed before starting any treatment. Understanding these risks is an important part of making a safe and informed decision.

Orlistat commonly causes gastrointestinal side effects, particularly when dietary fat intake is high. These include:

• Oily or fatty stools

• Frequent or urgent bowel movements

• Flatulence and abdominal discomfort

• Oily spotting on underwear

These effects are directly related to the mechanism of action and can be minimised by following a low-fat diet. Orlistat may also reduce the absorption of fat-soluble vitamins (A, D, E, and K), so a daily multivitamin supplement is often recommended. Importantly, the multivitamin should be taken at bedtime or at least two hours after taking orlistat to ensure adequate absorption.

Orlistat has important interactions with several medicines. It is contraindicated with ciclosporin (it can significantly reduce ciclosporin levels). Patients taking warfarin should have their INR monitored more closely, as orlistat may affect anticoagulant control. Those taking levothyroxine should separate the doses by at least four hours and have their thyroid function monitored. In rare cases, orlistat has been associated with severe liver injury and oxalate nephropathy (kidney stones). Patients should seek prompt medical advice if they develop itching, dark urine, yellowing of the skin or eyes, or pain in the upper right abdomen, as these may indicate liver problems.

GLP-1 receptor agonists such as semaglutide and liraglutide most commonly cause nausea, vomiting, diarrhoea, and constipation, particularly during the dose escalation phase. These symptoms often improve over time. In people with diabetes who are also taking insulin or sulfonylureas, there is an increased risk of hypoglycaemia (low blood sugar); a review of diabetes medication may be needed before starting a GLP-1 receptor agonist. More serious but less common risks include pancreatitis and gallbladder disease.

Regarding cardiovascular effects, GLP-1 receptor agonists are not known to increase the risk of major adverse cardiovascular events. Evidence from the SELECT trial (2023) suggests that semaglutide may reduce cardiovascular risk in people with established cardiovascular disease and overweight or obesity, though this benefit applies to a specific high-risk population.

Some regulatory reviews have examined a potential signal between GLP-1 receptor agonists and suicidal ideation or self-harm. To date, neither the MHRA nor the EMA has confirmed a causal link, but patients who experience low mood, thoughts of self-harm, or any significant change in mental health whilst taking these medicines should seek prompt medical advice.

Patients should seek urgent medical attention if they experience:

• Severe or persistent abdominal pain (which may indicate pancreatitis)

• Pain in the upper right abdomen, nausea, or jaundice (which may indicate gallstones or liver problems)

• Signs of a serious allergic reaction (swelling of the face, lips, or throat; difficulty breathing; rapid heartbeat)

Any suspected side effects from weight loss medicines should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

How to Access Weight Loss Medication Safely Through the NHS

The safest route to accessing weight loss medication in the UK is through the NHS or a regulated healthcare provider. Patients should begin by speaking with their GP, who can assess eligibility based on NICE criteria, review medical history, and either prescribe treatment directly or refer to a specialist weight management service.

NHS specialist weight management services (sometimes referred to as tier 3 or tier 4 services) offer a multidisciplinary approach, combining medical treatment with dietary advice, psychological support, and physical activity guidance. Referral to these services is typically required for newer treatments such as semaglutide and liraglutide, which NICE recommends be initiated and monitored within a specialist setting.

For those considering private options, it is essential to use only CQC-registered clinics and GPhC-registered pharmacies. Patients should be wary of websites offering prescription-only weight loss medicines without a valid consultation by a UK-registered prescriber, as this is both illegal and potentially dangerous. To verify that an online pharmacy is legitimate, look for the UK Distance Selling Logo on the website — this is the official symbol for registered online sellers of medicines in the UK. You can confirm registration via the MHRA's distance selling register and the GPhC's online pharmacy register (both available at their respective websites). The EU common logo is no longer the relevant verification mark for pharmacies operating in Great Britain.

Over-the-counter orlistat (Alli, 60 mg) is available from registered pharmacies without a prescription, but a pharmacist consultation is required before purchase to ensure suitability. Patients should never purchase weight loss products from unverified online sources, as these may contain unlicensed, counterfeit, or harmful ingredients. If in doubt, a pharmacist is an accessible and knowledgeable first point of contact for advice on safe weight management options.

Lifestyle Changes That Support Long-Term Weight Management

Weight loss medicines are most effective when used as part of a broader, sustained lifestyle programme. Clinical evidence consistently shows that medication alone produces modest results compared with the combination of pharmacological treatment and meaningful behavioural change. NICE guidance (CG189) emphasises that all weight management interventions should include support for dietary modification, increased physical activity, and behavioural strategies.

From a dietary perspective, a balanced, calorie-controlled diet remains the cornerstone of weight management. This does not mean extreme restriction, but rather a sustainable reduction in overall energy intake, with an emphasis on:

• Increasing fruit, vegetables, and fibre

• Reducing ultra-processed foods, added sugars, and saturated fats

• Eating regular meals to support appetite regulation

• Staying well hydrated

Physical activity plays an equally important role. NHS guidelines for adults recommend at least 150 minutes of moderate-intensity aerobic activity per week (or 75 minutes of vigorous-intensity activity), alongside muscle-strengthening activities on two or more days per week. Even modest increases in daily movement — such as walking more or taking the stairs — can contribute meaningfully to weight management and cardiovascular health.

Behavioural support, including cognitive behavioural techniques, goal-setting, and self-monitoring (such as keeping a food diary), has strong evidence behind it and is often offered through NHS tier 2 and tier 3 weight management programmes. Addressing psychological factors such as emotional eating, stress, and sleep quality is also important, as these can significantly influence eating behaviour and weight.

Ultimately, the goal is not rapid weight loss but sustainable, long-term change. Patients who engage with lifestyle support alongside any prescribed treatment are more likely to maintain weight loss after medication is discontinued, reducing the risk of weight regain and associated health complications.

Frequently Asked Questions